Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial ...

Merck is seeking approval of belzutifan in patients with advanced RCC based on data from the LITESPARK-005 trial (ClinicalTrials.gov Identifier: NCT04195750).

However, there was a PFS benefit with belzutifan over time. The 6-month PFS rate was 46.6% in the belzutifan arm and 42.5% in the everolimus arm. The 12-month PFS rate was 33.4% and 17.1% ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia ...

The approval makes belzutifan the first agent indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI. The oral hypoxia-inducible factor (HIF)-2 alpha ...

The combination of belzutifan and cabozantinib showed promising antitumor activity among patients with previously treated metastatic clear cell renal cell carcinoma, according to data published in ...

The researchers tested belzutifan and cabozantinib in the phase 2 LITESPARK-003 trial (NCT03634540), which enrolled patients with locally advanced or metastatic clear cell RCC who had received no ...

The Food and Drug Administration (FDA) has granted Priority Review to belzutifan for the potential treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC ...

The FDA on Friday approved Merck & Co Inc's (NYSE: MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau (VHL) disease. VHL is a rare genetic disease that causes tumors ...

The action establishes belzutifan as the only approved oral therapy for PPGL. The approval stipulates use in adults and children 12 years or older with locally advanced, unresectable, or ...

Research Summary Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease DOI: 10.1056/NEJMdo006263 The cause of von Hippel–Lindau disease is excess activity of the HIF-2α pathway.